Quince Therapeutics Inc (QNCX)

$0.10 -0.01 (-4.81%)
Market Cap 5.93M
Revenue (ttm) 0.00
Net Income (ttm) -56.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 16.53
Volume 11,289,500
Avg Vol 78,426,641
Day's Range N/A - N/A
Shares Out 55.68M
Stochastic %K 9%
Beta 1.28
Analysts Hold
Price Target $6.50

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
Nysurf
Nysurf Mar. 18 at 10:51 AM
$QNCX ... CASEY LYNCH... FUCK YOU ................. Dirk Thye ..... FUCK YOU what the next SCAM.. you fucking assholes
0 · Reply
Papluch
Papluch Mar. 18 at 10:34 AM
$QNCX
0 · Reply
robinraja1
robinraja1 Mar. 18 at 9:55 AM
$QNCX
0 · Reply
PaulLaurent
PaulLaurent Mar. 18 at 9:52 AM
🔄📉 Oversold Small Caps Update 🧪🔄 $LBGJ $YYGH $JEM $JDZG $QNCX
0 · Reply
TMoney07__
TMoney07__ Mar. 18 at 8:38 AM
$QNCX this could go with other sub 10 pennies running. Runs nicely with vol.
0 · Reply
AlienTrador
AlienTrador Mar. 18 at 3:28 AM
$QNCX
0 · Reply
rimbo90
rimbo90 Mar. 18 at 12:06 AM
$QNCX dogshit
0 · Reply
Trick2MoneyisHavingSum
Trick2MoneyisHavingSum Mar. 17 at 11:08 PM
$LNAI they're serious guys - the bulls that is jump in $QNCX $RGC
0 · Reply
Trick2MoneyisHavingSum
Trick2MoneyisHavingSum Mar. 17 at 9:44 PM
$LNAI come $QNCX boyz
1 · Reply
Bertie194968
Bertie194968 Mar. 17 at 9:39 PM
$QNCX AH not looking great volume has fallen off could be heading to new lows at this rate IMO.
0 · Reply
Latest News on QNCX
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Feb 12, 2026, 12:27 PM EST - 4 weeks ago

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Stock Explodes 300% On Strategic Review

Feb 10, 2026, 3:05 PM EST - 5 weeks ago

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Feb 9, 2026, 4:05 PM EST - 5 weeks ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 29, 2026, 3:10 PM EST - 6 weeks ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Jan 28, 2026, 4:05 PM EST - 6 weeks ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Jan 12, 2026, 11:08 AM EST - 2 months ago

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 15, 2025, 8:00 AM EST - 3 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Dec 10, 2025, 4:05 PM EST - 3 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 24, 2025, 8:00 AM EST - 4 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:05 PM EST - 4 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Nov 10, 2025, 4:05 PM EST - 4 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 9, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Oct 2, 2025, 5:12 PM EDT - 5 months ago

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 25, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Quince Therapeutics, Inc. - Special Call

Sep 24, 2025, 1:13 AM EDT - 6 months ago

Quince Therapeutics, Inc. - Special Call

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 11, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 16, 2025, 8:00 AM EDT - 8 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jul 10, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 18, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 9 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jun 3, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025, 9:50 AM EDT - 10 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 11 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics to Participate at Upcoming Investor Conferences

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Nysurf
Nysurf Mar. 18 at 10:51 AM
$QNCX ... CASEY LYNCH... FUCK YOU ................. Dirk Thye ..... FUCK YOU what the next SCAM.. you fucking assholes
0 · Reply
Papluch
Papluch Mar. 18 at 10:34 AM
$QNCX
0 · Reply
robinraja1
robinraja1 Mar. 18 at 9:55 AM
$QNCX
0 · Reply
PaulLaurent
PaulLaurent Mar. 18 at 9:52 AM
🔄📉 Oversold Small Caps Update 🧪🔄 $LBGJ $YYGH $JEM $JDZG $QNCX
0 · Reply
TMoney07__
TMoney07__ Mar. 18 at 8:38 AM
$QNCX this could go with other sub 10 pennies running. Runs nicely with vol.
0 · Reply
AlienTrador
AlienTrador Mar. 18 at 3:28 AM
$QNCX
0 · Reply
rimbo90
rimbo90 Mar. 18 at 12:06 AM
$QNCX dogshit
0 · Reply
Trick2MoneyisHavingSum
Trick2MoneyisHavingSum Mar. 17 at 11:08 PM
$LNAI they're serious guys - the bulls that is jump in $QNCX $RGC
0 · Reply
Trick2MoneyisHavingSum
Trick2MoneyisHavingSum Mar. 17 at 9:44 PM
$LNAI come $QNCX boyz
1 · Reply
Bertie194968
Bertie194968 Mar. 17 at 9:39 PM
$QNCX AH not looking great volume has fallen off could be heading to new lows at this rate IMO.
0 · Reply
Bertie194968
Bertie194968 Mar. 17 at 8:30 PM
$QNCX When will it receive a notice for not being in compliant with the NASDAQ? Is it 30 consecutive business days below $1.00
2 · Reply
klrkawa
klrkawa Mar. 17 at 8:13 PM
$ADIA amazing progress $QNCX
0 · Reply
Ph777trader
Ph777trader Mar. 17 at 8:12 PM
$QNCX
1 · Reply
CheckingMorons
CheckingMorons Mar. 17 at 8:05 PM
$QNCX it’s done on purpose at the moment
1 · Reply
victory369
victory369 Mar. 17 at 8:03 PM
$QNCX Under 0.10 cents 😁 not good
0 · Reply
makesomemoneybro123
makesomemoneybro123 Mar. 17 at 8:01 PM
$QNCX Officially just started the 10 days under 0.10! Let's see tomorrow
0 · Reply
CheckingMorons
CheckingMorons Mar. 17 at 7:44 PM
$QNCX sadly under 0.10 is not good
0 · Reply
victory369
victory369 Mar. 17 at 7:25 PM
$QNCX It’s will jump to $0.10 cents in the last minute 😁 it’s happened every day 😁
1 · Reply
VTHEKING
VTHEKING Mar. 17 at 7:25 PM
$QNCX cup and handle. Handle broke 💔 😪.
0 · Reply
_BUBBLES_
_BUBBLES_ Mar. 17 at 7:12 PM
$QNCX Volume is up almost 3 million compared to 3pm yesterday.
0 · Reply
Ph777trader
Ph777trader Mar. 17 at 6:09 PM
$QNCX bar code now ! Is cooking
0 · Reply
Wallstreetpenny
Wallstreetpenny Mar. 17 at 5:54 PM
$QNCX Merge already dammit!
1 · Reply